PARICALCITOL AS A CHEMOTHERAPEUTIC AGENT - CEDARS SINAI MEDICAL CENTER

Title:

PARICALCITOL AS A CHEMOTHERAPEUTIC AGENT

Document Type and Number:

WIPO Patent Application WO2004062620

Kind Code:

A3

Abstract:

The invention provides methods of reducing the severity of a proliferative disorder. One method involves administering to an individual having the proliferative disorder an effective amount of paricalcitol, wherein the paricalcitol reduces cellular proliferation, with the proviso that the cancer is not prostate cancer or head and neck squamous cell carcinoma. Another method of reducing the severity of a proliferative disorder provided by the invention involves administering to an individual having the proliferative disorder an effective amount of paricalcitol and an anti- cancer agent, wherein the combination of paricalcitol and the anti-cancer agent reduces cell proliferation, with the proviso that the proliferative disorder is not prostate cancer or head and neck squamous cell carcinoma.

More Like This:

WO/2009/115398	VITAMIN D COMPOUNDS FOR THE TREATMENT OF BILIARY DISEASES
JP2014514274	Polymorphism of maxacalcitol and preparation method of maxacalcitol
WO/2008/134523	METHOD OF SAFELY AND EFFECTIVELY TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE

Inventors:

KOEFFLER PHILLIP H (US)
KUMAGAI TAKASHI (JP)

Application Number:

PCT/US2004/000754

Publication Date:

November 25, 2004

Filing Date:

January 13, 2004

Export Citation:

Click for automatic bibliography generation Help

Assignee:

CEDARS SINAI MEDICAL CENTER (US)
KOEFFLER PHILLIP H (US)
KUMAGAI TAKASHI (JP)

International Classes:

A61K31/59; A61K; (IPC1-7): A61K31/59

Foreign References:

US6624138B1

2003-09-23

Download PDF:

View/Download PDF PDF Help

Previous Patent: SOLUBLE Fc?R FUSION PROTEINS AND METHODS OF USE THEREOF

Next Patent: ANTI-INFLAMMATORY AGENTS AND METHODS OF THEIR USE